Protagenic Therapeutics, Inc.
PTIX- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001022899
In the last 90 days, Protagenic Therapeutics, Inc. insiders filed 7 open-market purchases and 0 sales; 2 institutions reported holding it in 13F filings for Q2 2026, worth $25.4K in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Protagenic Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- +2 vs. Q1 2025
- Shares held
- 70.6K
- −267.1K (−79.1%) vs. Q1 2025
- Total value
- $258.1K
- +$192.2K (+291.8%) vs. Q1 2025
- New holders
- 7
- 0 more added
- Sold out
- 5
- 3 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTIX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 2 | $25.4K |
| Q1 2026 | 4 | $44.4K |
| Q4 2025 | 12 | $150.9K |
| Q3 2025 | 11 | $344.4K |
| Q2 2025 | 11 | $258.1K |
| Q1 2025 | 9 | $65.9K |
| Q4 2024 | 9 | $75.0K |
| Q3 2024 | 11 | $104.3K |
| Q2 2024 | 11 | $145.7K |
| Q1 2024 | 11 | $205.6K |
| Q4 2023 | 10 | $106.8K |
| Q3 2023 | 9 | $179.5K |
| Q2 2023 | 10 | $198.4K |
| Q1 2023 | 10 | $164.2K |
| Q4 2022 | 18 | $247.9K |
| Q3 2022 | 17 | $342.0K |
| Q2 2022 | 16 | $435.0K |
| Q1 2022 | 17 | $548.0K |
| Q4 2021 | 19 | $1.32M |
| Q3 2021 | 19 | $1.81M |
| Q2 2021 | 13 | $683.0K |
| Q1 2021 | 1 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Protagenic Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Virtu Financial LLC | 18,808 | $69.0K | 0.00% | −36,722−66.1% | Reduced |
| Alpine Global Management, LLC | 16,351 | $59.7K | 0.01% | +16,351 | New |
| Morgan Stanley | 15,002 | $54.8K | 0.00% | +15,002 | New |
| Susquehanna International Group, LLP | 10,156 | $37.1K | 0.00% | +10,156 | New |
| UBS Group AG | 9,020 | $32.9K | 0.00% | +9,020 | New |
| Tower Research Capital LLC (TRC) | 876 | $3.20K | 0.00% | −5,041−85.2% | Reduced |
| Citigroup Inc | 390 | $1.42K | 0.00% | +390 | New |
| Bank of America Corp | 6 | $23 | 0.00% | −48−88.9% | Reduced |
| Raymond James Financial Inc | 1 | $4 | 0.00% | +1 | New |
| Harbor Investment Advisory, LLC | 1 | $4 | 0.00% | +1 | New |
| CWM, LLC | 1 | $0 | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 0 | $0 | 0.00% | −124,015−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −77,296−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −33,166−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −27,968−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −13,812−100.0% | Sold out |